RASSF1 and Wilms tumor: Although p16INK4a(CDKN2a) promoter methylation has been reported in advanced stage Wilms' tumours (Arcellana-Panlilio et al, 2000), this trend was not significant in our series, and to date no specific clinicopathological features have been associated with SLIT2, CASP8 and RASSF1A methylation.